Cat. No. 3314
Chemical Name: 4-(2,3-Dihydro-1,4-benzodioxin-6-yl
Biological ActivityCompetitive c-Jun N-terminal kinase (JNK) inhibitor (IC50 = 280 nM) that displays > 100 fold selectivity over p38α and no activity at mTOR and PI-3K. Inhibits JNK interacting protein 1 (JIP1)-JNK binding (IC50 = 500 nM) and prevents JNK substrate phosphorylation. Blocks JNK-dependent Con A-induced liver damage and restores insulin sensitivity in a mouse model of type II diabetes.
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Certificate of Analysis / Product Datasheet / Safety Data Sheet
Flight (2008) Getting rid of JNK. Nat.Rev.Drug Disc. 7 975.
Haas and Writer (2008) Block JNK at the dock. SCiBX 1 1.
Stebbins et al (2008) Identification of a new JNK inhibitor targeting the JNK-JIP interaction site. Proc.Natl.Acad.Sci.USA 105 16809.
If you know of a relevant reference for this product please let us know.
Citations are publications that use Tocris products. Selected citations for BI 78D3 include:
Jang et al (2015) Critical role of c-jun N-terminal protein kinase in promoting mitochondrial dysfunction and acute liver injury. PLoS Biol 6 552. PMID: 26491845.
Eckle et al (2013) HIF1A reduces acute lung injury by optimizing carbohydrate metabolism in the alveolar epithelium. Br J Pharmacol 11 e1001665. PMID: 24086109.
Gandham et al (2013) Effects of Y27632 on keratinocyte procurement and wound healing. Redox Biol 38 782. PMID: 23675999.
Do you know of a great paper that uses BI 78D3 from Tocris? If so please let us know.
View Related Products by Product Action
Keywords: BI 78D3, supplier, Selective, competitive, JNK, inhibitors, inhibits, MAPK, Signaling, Signalling, c-Jun, N-Terminal, Kinases, SAPKs, Stress-Activated, Protein, Mitogen-Activated, p38, BI78D3, Tocris Bioscience, JNK/c-Jun Inhibitor products
Find multiple products by catalog number
New Products in this Area
Selective p38α/β inhibitor; orally bioavailableAX 15836
Potent and selective ERK5 inhibitor
Follow Tocris on LinkedIn
Visit our LinkedIn page for the latest Tocris news, events and updates.